The latest price target for Allogene Therapeutics (NASDAQ:ALLO) was reported by Piper Sandler on November 14, 2024. The analyst firm set a price target for $9.00 expecting ALLO to rise to within 12 months (a possible 327.55% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Allogene Therapeutics (NASDAQ:ALLO) was provided by Piper Sandler, and Allogene Therapeutics maintained their overweight rating.

The last upgrade for Allogene Therapeutics Inc happened on January 24, 2023 when JP Morgan raised their price target to $11. JP Morgan previously had a neutral for Allogene Therapeutics Inc.

The last downgrade for Allogene Therapeutics Inc happened on January 5, 2024 when Guggenheim changed their price target from N/A to N/A for Allogene Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a maintained with a price target of $11.00 to $9.00. The current price Allogene Therapeutics (ALLO) is trading at is $2.11, which is out of the analyst’s predicted range.